OR WAIT null SECS
June 06, 2019
A new United Kingdom life-science asset, HIRANI, was launched at a reception at BIO in Philadelphia.
ERS Genomics and Bioneer have revealed the signing of a license agreement for access to CRISPR/Cas9 genome editing technology intellectual property.
CPI, has supported a project focused on developing and integrating novel recombinant prokaryotic lectins (RPLs) into a biosensor-based platform.
Gene therapy development company, bluebird bio, has revealed that the European Commission has granted conditional marketing authorization for Zynteglo.
May 31, 2019
Prestige BioPharma has announced that the EMA has accepted its marketing authorization application for HD201 (Tuzune) for review.
CDMO, Vibalogics, has revealed that it will be acquired by a private equity firm, Ampersand Capital Partners.
May 30, 2019
Nanobiotix has launched Curadigm, a spinoff company that will specialize in developing a nanotechnology platform for healthcare applications.
A new facility to be built in the Philadelphia Navy Yard will support commercial production for autologous tumor-infiltrating lymphocyte cell therapy products from Iovance Biotherapeutics.
May 28, 2019
Eli Lilly is set to acquire exclusive worldwide rights for potential non-opioid treatment CNTX-0290 from Centrexion Therapeutics in a deal potentially worth $997.5 million.
The company says it will work with payers to create payment options for its recently approved gene therapy, Zolgensma (onasemnogene abeparvovec-xioi), priced at $2.125 million.